Scientific Advisory Board
Charles L. Wiseman, MD, FACP
Founder and Principal Research Advisor
Dr. Wiseman brings more than 40 years of academic and clinical experience to BriaCell Therapeutics Corp. As Co-Founder of BriaCell, he is the inventor for most of the Company’s intellectual property and actively participates in its ongoing technology development. During his career, Dr. Wiseman has managed numerous clinical development teams and programs, with a focus in oncology, tumor immunology, vaccine development, and genetics. | Show More
Doug Faller, MD, PhD
Dr. Faller is a Professor of Medicine, Pediatrics, Biochemistry, Microbiology, Pathology and Laboratory Medicine; former Director of the Cancer Center; and former Vice-Chairman, Division of Medicine, of Boston University School of Medicine. He is a hematologist/oncologist, author of hundreds of scientific papers and recipient of numerous grants. He is an acknowledged expert in basic molecular and cellular biology of virus- and oncogene-transformed cells and tumors. | Show More
Cara L. Haymaker, PhD
Dr. Cara Haymaker is an assistant professor at Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine at The University of Texas MD Anderson Cancer Center. She has been appointed as Director, CCSG Oncology Research and Immunomonitoring Core, Department of Translational Molecular Pathology, Division of Pathology and Lab Medicine since 2018, and as Faculty Member, Translational Molecular Pathology Immunoprofiling Laboratory (TMP-IL) since 2016 at MD Anderson. | Show More
Alexander Kharazi, MD, PhD
Dr. Kharazi co-invented Bria-IMT™, BriaCell’s lead clinical candidate, in collaboration with Dr. Charles L. Wiseman, BriaCell’s Founder and Principal Research Advisor. Dr. Kharazi currently serves as Chief Technology Officer at Stemedica Cell Technologies, Inc. His experience includes roles as Chief Scientist of the Immunotherapy laboratory at St. Vincent Medical Center in Los Angeles (1998-2006) and Chief Pathologist of a large good laboratory practice (GLP) animal study at the University of California, Los Angeles (UCLA) (1991-1998) reporting results to the U.S. Congress. | Show More
Thomas Kieber-Emmons, PhD
Dr. Kieber-Emmons is known for his work on molecular and structural immunology, developing peptide mimetics of carbohydrate antigens as vaccines in both the cancer and pathogen areas, an acknowledged pioneer in this field. Dr. Kieber-Emmons has both translational and clinical trial experience. Dr. Kieber-Emmons has brought the first carbohydrate mimetic peptide through preclinical development to Phase II Clinical Trials in Breast Cancer and in other cancer indications. | Show More
Brian Metcalf, PhD
Dr. Metcalf recently retired as CSO from Global Blood Therapeutics. GBT currently has a Phase III study underway with GBT440 for sickle cell anemia. Earlier he served as head, drug discovery at Incyte Pharmaceuticals. During his tenure at Incyte, the company was transformed from a genomics information company to one focused on drug discovery, culminating in the discovery of Jakafi, a JAK1/2 kinase inhibitor. | Show More
Maria Trojanowska, PhD
Dr. Trojanowska is a Professor of Medicine and Director of the Arthritis Center at the Boston University School of Medicine. An expert in immunology and fibrotic diseases, her research focuses on the molecular and cellular mechanisms that underlie pathogenic processes responsible for tissue fibrosis and vasculopathy in scleroderma.
Suzanne Ostrand-Rosenberg, PhD
Dr. Ostrand-Rosenberg has more than 40 years of experience leading investigations focused on the immune system’s response to cancer. She is currently the Robert & Jane Meyerhoff Professor of Biochemistry, Emeritus, and Professor of Biological Sciences, Emeritus, University of Maryland Baltimore County, Baltimore, MD, and has been working with the University since 1977. She was also appointed as the Adjunct Professor of Pathology, Huntsman Cancer Institute (HCI), University of Utah, Salt Lake City, UT, in 2018. | Show More
Charles Sidman, PhD, MBA
Dr. Sidman currently serves as Founder and Managing Partner, ECS Capital Partners, LLC. Dr. Sidman’s academic career includes experience as Research Fellow in Pathology at Harvard Medical School, Member of the Basel Institute for Immunology in Basel, Staff Scientist at The Jackson Laboratory in Bar Harbor, and Professor of Molecular Genetics, Biochemistry, Microbiology, and Management at the University of Cincinnati. His first professional effort was in computer science, in which he pioneered what became known decades later as Artificial Intelligence. In biomedicine, he worked with eminent colleagues in genetics and immunology to help enable current exciting applications in these fields. | Show More